

13 Jul 2021

Bristol-Myers Squibb International Corporation

Email: Clinical.Trials@bms.com

Chaussée de la Hulpe 185

Brussels, Belgium

1170

EudraCT Number: 2017-003059-46

Sponsor Protocol Number: CA017-063

A Randomized, Global, Open-label Study of Nivolumab in Combination with BMS-986205 vs  
Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell  
Carcinoma of Head and Neck

Trial 2017-003059-46 was withdrawn with 0 patients enrolled. As such no results are reported.